Kylnetta (Drospirenone, Ethinylestradiol)

Drospirenone acts as a progestin with anti‑mineralocorticoid properties, while ethinylestradiol supplies estrogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, reducing LH and FSH release, which blocks ovulation. They also thicken cervical mucus and alter the endometrium, making implantation unlikely.

The dosing regimen for Kylnetta is determined by the prescribing clinician based on the product’s labeling and the patient’s individual needs. Healthcare providers select the appropriate tablet strength and schedule; patients should follow the prescriber’s instructions exactly.

Kylnetta is contraindicated during pregnancy because it is intended to prevent conception, not to treat an existing pregnancy. Its safety during breastfeeding has not been established, and clinicians typically advise against use while nursing unless the benefits outweigh potential risks.

To order Kylnetta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kylnetta contains drospirenone, a progestin with anti‑mineralocorticoid activity, which may offer a lower risk of water retention compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, but individual side‑effect profiles can differ.

Kylnetta tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep them in the original blister pack, away from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Kylnetta is taken orally, usually once daily at the same time each day, as directed by the prescribing clinician. The typical regimen involves a 21‑day active tablet series followed by a hormone‑free interval, but exact instructions depend on the specific product labeling.

Serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe allergic reactions and hepatic complications may also occur. Patients should seek immediate medical attention if they experience symptoms like sudden leg pain, shortness of breath, or severe rash.

Kylnetta is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, certain cardiovascular diseases, active liver disease, or who smoke cigarettes and are over 35 years of age. It should also be avoided in individuals with known hypersensitivity to drospirenone, ethinylestradiol, or any excipients.